SKBR3 cells are characterized by co-amplification of the genes coding for HER2 and the nuclear retinoic acid receptor, RARα, and they are representative of a novel subgroup of HER2+ breast tumors with selective sensitivity to simultaneous targeting of RARα with ATRA and HER2 with Lapatinib [1]. This evidence concerns the gene ERBB2 and breast neoplasm.